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Dear Editor, 26 
 27 
Pheochromocytomas (PCCs) are rare catecholamine-secreting tumors arising from the 28 
chromaffin cells in the adrenal medulla. Closely related paragangliomas share 29 
developmental origin but arise extra-adrenally, in the paraganglia that belongs to the 30 
sympathetic and parasympathetic ganglia. Most PCCs are sporadic but around 25%-30% of 31 
them are associated with familial syndromes caused by germline mutations of at least ten 32 
genes (Gimenez-Roqueplo et al. 2012). The low incidence of pheochromocytomas poses 33 
difficulties to the development of diagnostic or prognostic markers as well as effective 34 
therapies and thus the development of novel animal and cellular models for the study of the 35 
disease is needed. Sprouty (Spry) family of genes is composed of four members of feedback 36 
inhibitors of receptor tyrosine kinase signaling, that specifically target the MAPK pathway. 37 
As such, they have been proposed as tumor suppressors in several cancerous pathologies 38 
such as tumors of the prostate, thyroid or liver (Masoumi-Moghaddam et al. 2014). Here 39 
we present a novel mouse model of pheochromocytoma consisting of double heterozygous 40 
mice for Pten and Spry1. These animals develop pheochromocytomas that appear at earlier 41 
onset and grow at higher rate than those from Pten+/- mice. 42 
In a previous report we have found that mouse bearing a Spry1 null mutation in the context 43 
of Pten haploinsufficiency developed thyroid hyperplasia at higher frequencies and earlier 44 
onset than Pten+/- littermates (Macià et al. 2014). While examining thyroid glands from 45 
these animals we noticed that Pten+/- ; Spry1+/- mice also developed thyroid hyperplasia 46 
with a frequency comparable to that of Pten+/- ; Spry1-/- mice at three months of age (data 47 
not shown), indicating that deletion of a single Spry1 allele was enough to accelerate 48 
thyroid tumorigenesis in the context of Pten haploinsufficiency. We therefore looked for 49 
tumor formation in tissues from Pten+/- ; Spry1+/- double heterozygous mice in other tissues, 50 
including the adrenal gland, which expresses high levels of Spry1 by real time PCR (data 51 
not shown). Histological analysis mice at five months of age revealed that roughly one third 52 
(9/28; 32%) of adrenal glands from double heterozygous mice presented 53 
pheochromocytoma, compared to 17% (3/18) of adrenals from Pten+/- mice (Figures 1A 54 
and 1B). In these lesions the alveolar or “nested” pattern found on normal medullae was 55 
replaced by more densely packed sheets or cords of cells that compressed the adjacent 56 
cortical parenchyma (Figure 1A). Most of the remaining adrenal glands of double 57 
heterozygous mice (15/28; 50%) developed hyperplastic nodules (Tischler et al. 2004) in 58 
their medullae (Figures 1A and 1B), which were similar in morphology to 59 
pheochromocytomas but did not compress the adrenal cortex. In contrast, only 4 out of 18 60 
glands (22%) from Pten+/- mice developed nodular hyperplasia at this age, being the 61 
remaining 60% normal. Overall, at five months of age more than 80% of double mutant 62 
mice compared to around 40% of Pten+/- mice showed neoplastic lesions of the adrenal 63 
medulla. Medullae from Spry1+/- mice were normal in all cases and at all ages analyzed 64 
(Figure 1A). Tumors from both Pten+/- and double heterozygous mice stained positive for 65 
tyrosine hydroxylase, demonstrating their chromaffin origin (Figure 1C). We next 66 
conducted loss of heterozygosity analysis by PCR, using primers flanking a FRT site 67 
present in the knockout but not the wild type allele (Basson et al. 2005). Capillary 68 
electrophoresis fragment analysis indicated that the wild type allele was retained in ten out 69 
of ten pheochromocytomas from double heterozygous mice analyzed (Figure 1D). 70 
Moreover, immunoblot analysis of Sprouty1 levels from pheochromocytomas using a 71 
specific antibody (D9V6P, Cell Signaling Technologies) clearly showed that expression of 72 
Sprouty1 was not lost in five out of six tumors from double heterozygous mice (Figure 1E). 73 
Interestingly, Sprouty1 protein levels were reduced in pheochromocytomas from double 74 
heterozygous mice when compared to Pten+/- mice, likely reflecting that Spry1 behaves as a 75 
dosage-sensitive gene. This is in agreement with our previous findings indicating that Spry1 76 
also behaves as a dosage-sensitive gene during genito-urinary development as deletion of a 77 
single allele of Spry1 partially rescues renal agenesis caused by Ret mutation (Rozen et al. 78 
2009). In conclusion, loss of a single allele of Spry1 in the context of Pten 79 
haploinsufficiency significantly (P=0.01, Chi-square test) accelerated the appearance of 80 
neoplastic lesions of the adrenal medulla. Immunocytochemistry and western blot analysis 81 
also indicated that Pten expression was frequently lost in pheochromocytomas from both 82 
genotypes (data not shown). By nine months of age virtually all double heterozygous mice 83 
examined presented either pheochromocytoma (21/32; 66%) or nodular hyperplasia (9/32; 84 
28%), whereas 14/30 (47%) and 12/30 (40%) of Pten+/- adrenal glands did (Figure 2C). 85 
These differences were not statistically significant (P=0.29, Chi-square test), however 86 
adrenal glands from double heterozygous mice were on average almost four times bigger 87 
than those from Pten+/- mice  (Figures 2A and 2B). Thus, adrenal glands from Spry1+/- mice 88 
had a mean volume of 0.79 ± 0.19 mm3 (mean ± standard error) compared to 2.64±0.51 89 
mm3 (Pten+/-) and 8.28 ±1.77 mm3 (Pten+/-; Spry1+/-). Differences in adrenal size between 90 
Pten+/- and Pten+/-; Spry1+/- mice were highly significant (P=0.0001 by Mann-Whitney test). 91 
The number of mitotic figures per 10 high power fields was also significantly higher in 92 
pheochromocytoma from double heterozygous mice than those from Pten+/- mice [(P=0.033 93 
by Mann-Whitney test), Figure 2D]. Five out of 14 (36%) Pten+/- pheochromocytomas 94 
presented more than 3 mitoses per ten high power field, whereas 15 out of 21 (71%) of 95 
Pten+/-; Spry1+/- did. These differences presented a trend towards but did not reach 96 
statistical significance (P=0.07, Chi-square test). Finally, tyrosine hydroxylase or 97 
synaptophysin staining revealed that larger glands from double heterozygous mice but not 98 
Pten+/- mice often presented chromaffin cells invading the adrenal cortex or breaking 99 
through the adrenal capsule (Figure 2E). Although tumor-associated criteria reliably 100 
predicting malignancy in pheochromocytoma are not available, tumor size, local invasion 101 
or mitotic index have been proposed as signs of malignancy by several authors (Mete et al. 102 
2014). In conclusion, our data demonstrate that loss of a single allele of Spry1 accelerates 103 
both the onset of pheochromocytoma formation and the growth rate of these tumors. We 104 
currently do not know by which mechanism Spry1 restrains growth of pheochromocytoma 105 
cells but several possibilities deserve future attention. Transcriptomic analysis of human 106 
pheochromocytomas and paragangliomas reveals two different clusters characterized by 107 
distinct expression signatures (Gimenez-Roqueplo et al. 2012). Cluster one (comprising 108 
mutations of SDHx, FH, VHL, or HIF2A) presents a pseudo-hypoxia signature 109 
characterized by a switch from oxidative phosphorylation to aerobic glycolysis (Warburg 110 
effect), whereas cluster two (mutations of RET, NF1, TMEM127, or MAX) reflects 111 
aberrant activation of the MAPK and mTOR pathways. One mechanism worth exploring 112 
would be ectopic activation of the MAPK kinase pathway upon Spry1 loss. Interestingly, 113 
Spry1 and Spry2 antagonize Ret signaling during renal and enteric nervous system 114 
development, via inhibition of the MAPK (and the PI3-K) pathways (Masoumi-115 
Moghaddam et al. 2014). On the other hand, our previous work points to a role of Spry1 in 116 
inducing cellular senescence as a mechanism of tumor suppression in the thyroid gland 117 
(Macià et al. 2012)(Macià et al. 2014). Similarly, induction of cellular senescence could 118 
account for the protective effects of Spry1 in pheochromocytoma development. In line with 119 
this hypothesis You and colleagues have demonstrated that pheochromocytoma incidence 120 
in Pten+/- mice dramatically increases upon concomitant deletion of the Ink4a/Arf locus, a 121 
master regulator of cellular senescence (You et al. 2002). Recent studies demonstrate that 122 
escape from senescence is accompanied by a metabolic switch from oxidative 123 
phosphorylation to aerobic glycolysis (Kaplon et al. 2013), much like the pseudo-hypoxic 124 
response found in cluster one. In any case, further studies are required to determine whether 125 
Spry1 restricts pheochromocytoma growth by inhibiting the MAPK pathway, by inducing 126 
cellular senescence or a combination of both. 127 
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FIGURE LEGENDS 145 
 146 
Figure 1. (A) Representative images of hematoxylin-eosin stained adrenal glands from five 147 
month-old mice of the indicated genotypes. Arrowhead points to a hyperplastic nodule, 148 
noted as N in the lower panel. (B) Frequencies of pheochromocytoma, nodular hyperplasia 149 
or normal medullae in five month-old mice of the indicated genotypes. (C) Tyrosine 150 
hydroxylase staining of adrenal glands from five month-old mice of the indicated 151 
genotypes. D) Representative results of loss of heterozygosity analysis of DNA from 152 
tumoral vs. normal tissues from two nine month-old double heterozygous mice. (E) The 153 
amount of Sprouty1 in pheochromocytomas from mice of the indicated phenotypes was 154 
assessed by immunoblot. The two upper panels are different exposures of the same blot to 155 
show lack of immunoreactivity in the first lane, corresponding to adrenal medulla from 156 
Spry1 knockout mice. Equal loading was assessed by actin immunoblot. NS: non-specific 157 
band. 158 
 159 
Figure 2. (A) Macroscopic images, (B) gland volume, (C) tumor frequency, and (D) 160 
number of mitoses per ten high power fields of adrenal glands from nine month-old mice of 161 
the indicated genotypes. (E) Tyrosine hydroxylase and synaptophysin staining showing 162 
capsular invasion of pheochromocytoma cells of nine month-old Pten+/-; Spry1+/- mice. 163 
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